{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:12:23Z","timestamp":1790835143143,"version":"4.1.0"},"posted":{"date-parts":[[2023,7,7]]},"group-title":"In Review","reference-count":54,"publisher":"Research Square Platform LLC","license":[{"start":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T00:00:00Z","timestamp":1688688000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,7,4]]},"abstract":"<title>Abstract<\/title>\n        <p>Serotonergic psychedelics such as psilocybin, lysergic acid diethylamide, and DOI exert a hallucinatory effect through serotonin 5-HT 2A receptor (5-HT2A) activation. Recent studies have revealed that serotonergic psychedelics have therapeutic potential for neuropsychiatric disorders, including major depressive and anxiety-related disorders. However, the involvement of 5-HT2A in mediating the therapeutic effects of these drugs remains unclear. In this study, we ethopharmacologically analyzed the role of 5-HT2A in the occurrence of anxiolytic-and antidepressant-like effects of serotonergic psychedelics such as psilocin, an active metabolite of psilocybin, DOI, and TCB-2 in mice. Mice with acute intraperitoneal psychedelic treatment exhibited significantly shorter immobility times in the forced swimming test (FST) and tail-suspension test (TST) than vehicle-treated control mice 24 h post-treatment. These effects were eliminated by pretreatment with volinanserin, a 5-HT2A antagonist. Surprisingly, the decreasing immobility time in the FST in response to acute psilocin treatment was sustained for at least three weeks. In the novelty-suppressed feeding test (NSFT), the latency to feed, an indicator of anxiety-like behavior, was decreased by acute administration of psilocin; however, pretreatment with volinanserin did not diminish this effect. In contrast, DOI and TCB-2 did not affect the NSFT performance in mice. Furthermore, psilocin, DOI, and TCB-2 treatment did not affect the spontaneous locomotor activity or head-twitch response, a hallucination-like behavior in rodents. These results suggest that 5-HT2A contributes to the antidepressant effects of serotonergic psychedelics rather than an anxiolytic effects.<\/p>","DOI":"10.21203\/rs.3.rs-3138705\/v1","type":"posted-content","created":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T14:16:44Z","timestamp":1688739404000},"source":"Crossref","is-referenced-by-count":2,"title":["Ethopharmacological evaluation of antidepressant-like effect of serotonergic psychedelics in C57BL\/6J male mice"],"prefix":"10.21203","author":[{"given":"Rika","family":"Takaba","sequence":"first","affiliation":[{"name":"Meijo University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Ibi","sequence":"additional","affiliation":[{"name":"Meijo University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Meijo University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Hosomi","sequence":"additional","affiliation":[{"name":"Meijo University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ririna","family":"Kawase","sequence":"additional","affiliation":[{"name":"Meijo University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Kitagawa","sequence":"additional","affiliation":[{"name":"Meijo University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Goto","sequence":"additional","affiliation":[{"name":"Meijo University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuki","family":"Achiwa","sequence":"additional","affiliation":[{"name":"Meijo University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kento","family":"Mizutani","sequence":"additional","affiliation":[{"name":"Meijo University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyosuke","family":"Maede","sequence":"additional","affiliation":[{"name":"Meijo University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Gonz\u00e1lez-Maeso","sequence":"additional","affiliation":[{"name":"Virginia Commonwealth University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Kitagaki","sequence":"additional","affiliation":[{"name":"Meijo University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Hiramatsu","sequence":"additional","affiliation":[{"name":"Meijo University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"8761","reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jad.2018.07.077","article-title":"Characterizing the course of suicidal ideation response to ketamine","volume":"241","author":"Ballard ED","year":"2018","unstructured":"Ballard ED, Yarrington JS, Farmer CA, Richards E, Machado-Vieira R, Kadriu B, Niciu MJ, Yuan P, Park L, Zarate CA, Jr. (2018) Characterizing the course of suicidal ideation response to ketamine. J Affect Disord 241: 86\u201393","journal-title":"J Affect Disord"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman RM","year":"2000","unstructured":"Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47: 351\u2013354","journal-title":"Biol Psychiatry"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1021\/jm000339w","article-title":"Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines","volume":"43","author":"Blair JB","year":"2000","unstructured":"Blair JB, Kurrasch-Orbaugh D, Marona-Lewicka D, Cumbay MG, Watts VJ, Barker EL, Nichols DE (2000) Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines. J Med Chem 43: 4701\u20134710","journal-title":"J Med Chem"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41586-020-3008-z","article-title":"A non-hallucinogenic psychedelic analogue with therapeutic potential","volume":"589","author":"Cameron LP","year":"2021","unstructured":"Cameron LP, Tombari RJ, Lu J, Pell AJ, Hurley ZQ, Ehinger Y, Vargas MV, McCarroll MN, Taylor JC, Myers-Turnbull D, Liu T, Yaghoobi B, Laskowski LJ, Anderson EI, Zhang G, Viswanathan J, Brown BM, Tjia M, Dunlap LE, Rabow ZT, Fiehn O, Wulff H, McCorvy JD, Lein PJ, Kokel D, Ron D, Peters J, Zuo Y, Olson DE (2021) A non-hallucinogenic psychedelic analogue with therapeutic potential. Nature 589: 474\u2013479","journal-title":"Nature"},{"key":"ref5","author":"Can A","year":"2012","unstructured":"Can A, Dao DT, Terrillion CE, Piantadosi SC, Bhat S, Gould TD (2012) The tail suspension test. J Vis Exp: e3769"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1126\/science.abl8615","article-title":"Structure-based discovery of nonhallucinogenic psychedelic analogs","volume":"375","author":"Cao D","year":"2022","unstructured":"Cao D, Yu J, Wang H, Luo Z, Liu X, He L, Qi J, Fan L, Tang L, Chen Z, Li J, Cheng J, Wang S (2022) Structure-based discovery of nonhallucinogenic psychedelic analogs. Science 375: 403\u2013411","journal-title":"Science"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of Psilocybin versus Escitalopram for Depression","volume":"384","author":"Carhart-Harris R","year":"2021","unstructured":"Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, Martell J, Blemings A, Erritzoe D, Nutt DJ (2021) Trial of Psilocybin versus Escitalopram for Depression. N Engl J Med 384: 1402\u20131411","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","article-title":"Psilocybin with psychological support for treatment-resistant depression: six-month follow-up","volume":"235","author":"Carhart-Harris RL","year":"2018","unstructured":"Carhart-Harris RL, Bolstridge M, Day CMJ, Rucker J, Watts R, Erritzoe DE, Kaelen M, Giribaldi B, Bloomfield M, Pilling S, Rickard JA, Forbes B, Feilding A, Taylor D, Curran HV, Nutt DJ (2018) Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology (Berl) 235: 399\u2013408","journal-title":"Psychopharmacology (Berl)"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study","volume":"3","author":"Carhart-Harris RL","year":"2016","unstructured":"Carhart-Harris RL, Bolstridge M, Rucker J, Day CM, Erritzoe D, Kaelen M, Bloomfield M, Rickard JA, Forbes B, Feilding A, Taylor D, Pilling S, Curran VH, Nutt DJ (2016) Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry 3: 619\u2013627","journal-title":"Lancet Psychiatry"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial","volume":"78","author":"Davis AK","year":"2021","unstructured":"Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, Finan PH, Griffiths RR (2021) Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry 78: 481\u2013489","journal-title":"JAMA Psychiatry"},{"key":"ref11","volume-title":"Lysergic acid diethylamide (LSD) promotes social behavior through mTORC1 in the excitatory neurotransmission","author":"Gregorio D","year":"2021","unstructured":"De Gregorio D, Popic J, Enns JP, Inserra A, Skalecka A, Markopoulos A, Posa L, Lopez-Canul M, Qianzi H, Lafferty CK, Britt JP, Comai S, Aguilar-Valles A, Sonenberg N, Gobbi G (2021) Lysergic acid diethylamide (LSD) promotes social behavior through mTORC1 in the excitatory neurotransmission. Proc Natl Acad Sci U S A 118"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.biopsych.2012.03.003","article-title":"Antidepressant effects of fibroblast growth factor-2 in behavioral and cellular models of depression","volume":"72","author":"Elsayed M","year":"2012","unstructured":"Elsayed M, Banasr M, Duric V, Fournier NM, Licznerski P, Duman RS (2012) Antidepressant effects of fibroblast growth factor-2 in behavioral and cellular models of depression. Biol Psychiatry 72: 258\u2013265","journal-title":"Biol Psychiatry"},{"key":"ref13","first-page":"720","article-title":"Demystifying serotonin syndrome (or serotonin toxicity)","volume":"64","author":"Foong AL","year":"2018","unstructured":"Foong AL, Grindrod KA, Patel T, Kellar J (2018) Demystifying serotonin syndrome (or serotonin toxicity). Can Fam Physician 64: 720\u2013727","journal-title":"Can Fam Physician"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.pnpbp.2015.06.006","article-title":"Long-term effects of repeated social stress on the conditioned place preference induced by MDMA in mice","volume":"63","author":"Garcia-Pardo MP","year":"2015","unstructured":"Garcia-Pardo MP, Blanco-Gandia MC, Valiente-Lluch M, Rodriguez-Arias M, Minarro J, Aguilar MA (2015) Long-term effects of repeated social stress on the conditioned place preference induced by MDMA in mice. Prog Neuropsychopharmacol Biol Psychiatry 63: 98\u2013109","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.neuron.2007.01.008","article-title":"Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior","volume":"53","author":"Gonzalez-Maeso J","year":"2007","unstructured":"Gonzalez-Maeso J, Weisstaub NV, Zhou M, Chan P, Ivic L, Ang R, Lira A, Bradley-Moore M, Ge Y, Zhou Q, Sealfon SC, Gingrich JA (2007) Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron 53: 439\u2013452","journal-title":"Neuron"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression","volume":"387","author":"Goodwin GM","year":"2022","unstructured":"Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC, Bird C, Blom RE, Brennan C, Brusch D, Burke L, Campbell-Coker K, Carhart-Harris R, Cattell J, Daniel A, DeBattista C, Dunlop BW, Eisen K, Feifel D, Forbes M, Haumann HM, Hellerstein DJ, Hoppe AI, Husain MI, Jelen LA, Kamphuis J, Kawasaki J, Kelly JR, Key RE, Kishon R, Knatz Peck S, Knight G, Koolen MHB, Lean M, Licht RW, Maples-Keller JL, Mars J, Marwood L, McElhiney MC, Miller TL, Mirow A, Mistry S, Mletzko-Crowe T, Modlin LN, Nielsen RE, Nielson EM, Offerhaus SR, O'Keane V, Palenicek T, Printz D, Rademaker MC, van Reemst A, Reinholdt F, Repantis D, Rucker J, Rudow S, Ruffell S, Rush AJ, Schoevers RA, Seynaeve M, Shao S, Soares JC, Somers M, Stansfield SC, Sterling D, Strockis A, Tsai J, Visser L, Wahba M, Williams S, Young AH, Ywema P, Zisook S, Malievskaia E (2022) Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. N Engl J Med 387: 1637\u20131648","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/02698811211073759","article-title":"Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up","volume":"36","author":"Gukasyan N","year":"2022","unstructured":"Gukasyan N, Davis AK, Barrett FS, Cosimano MP, Sepeda ND, Johnson MW, Griffiths RR (2022) Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. J Psychopharmacol 36: 151\u2013158","journal-title":"J Psychopharmacol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.vascn.2014.07.003","article-title":"Role of 5-HT(1A)- and 5-HT(2A) receptors for the murine model of the serotonin syndrome","volume":"70","author":"Haberzettl R","year":"2014","unstructured":"Haberzettl R, Fink H, Bert B (2014) Role of 5-HT(1A)- and 5-HT(2A) receptors for the murine model of the serotonin syndrome. J Pharmacol Toxicol Methods 70: 129\u2013133","journal-title":"J Pharmacol Toxicol Methods"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.neuropharm.2011.01.017","article-title":"Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens","volume":"61","author":"Halberstadt AL","year":"2011","unstructured":"Halberstadt AL, Geyer MA (2011) Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology 61: 364\u2013381","journal-title":"Neuropharmacology"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1177\/0269881110388326","article-title":"Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice","volume":"25","author":"Halberstadt AL","year":"2011","unstructured":"Halberstadt AL, Koedood L, Powell SB, Geyer MA (2011) Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice. J Psychopharmacol 25: 1548\u20131561","journal-title":"J Psychopharmacol"},{"key":"ref21","volume-title":"Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice","author":"Hesselgrave N","year":"2021","unstructured":"Hesselgrave N, Troppoli TA, Wulff AB, Cole AB, Thompson SM (2021) Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice. Proc Natl Acad Sci U S A 118"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1021\/acschemneuro.9b00493","article-title":"Psychedelics, but Not Ketamine, Produce Persistent Antidepressant-like Effects in a Rodent Experimental System for the Study of Depression","volume":"11","author":"Hibicke M","year":"2020","unstructured":"Hibicke M, Landry AN, Kramer HM, Talman ZK, Nichols CD (2020) Psychedelics, but Not Ketamine, Produce Persistent Antidepressant-like Effects in a Rodent Experimental System for the Study of Depression. ACS Chem Neurosci 11: 864\u2013871","journal-title":"ACS Chem Neurosci"},{"key":"ref23","first-page":"107","article-title":"[Psilocybin, a psychotropic substance from the Mexican mushroom Psilicybe mexicana Heim]","volume":"14","author":"Hofmann A","year":"1958","unstructured":"Hofmann A, Heim R, Brack A, Kobel H (1958) [Psilocybin, a psychotropic substance from the Mexican mushroom Psilicybe mexicana Heim]. Experientia 14: 107\u2013109","journal-title":"Experientia"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1038\/nn.4616","article-title":"Antipsychotic-induced Hdac2 transcription via NF-kappaB leads to synaptic and cognitive side effects","volume":"20","author":"Ibi D","year":"2017","unstructured":"Ibi D, de la Fuente Revenga M, Kezunovic N, Muguruza C, Saunders JM, Gaitonde SA, Moreno JL, Ijaz MK, Santosh V, Kozlenkov A, Holloway T, Seto J, Garcia-Bea A, Kurita M, Mosley GE, Jiang Y, Christoffel DJ, Callado LF, Russo SJ, Dracheva S, Lopez-Gimenez JF, Ge Y, Escalante CR, Meana JJ, Akbarian S, Huntley GW, Gonzalez-Maeso J (2017) Antipsychotic-induced Hdac2 transcription via NF-kappaB leads to synaptic and cognitive side effects. Nat Neurosci 20: 1247\u20131259","journal-title":"Nat Neurosci"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3389\/fncel.2020.00285","article-title":"Reelin Supplementation Into the Hippocampus Rescues Abnormal Behavior in a Mouse Model of Neurodevelopmental Disorders","volume":"14","author":"Ibi D","year":"2020","unstructured":"Ibi D, Nakasai G, Koide N, Sawahata M, Kohno T, Takaba R, Nagai T, Hattori M, Nabeshima T, Yamada K, Hiramatsu M (2020) Reelin Supplementation Into the Hippocampus Rescues Abnormal Behavior in a Mouse Model of Neurodevelopmental Disorders. Front Cell Neurosci 14: 285","journal-title":"Front Cell Neurosci"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.bbr.2016.09.011","article-title":"Chronic social defeat stress leads to changes of behaviour and memory-associated proteins of young mice","volume":"316","author":"Jianhua F","year":"2017","unstructured":"Jianhua F, Wei W, Xiaomei L, Shao-Hui W (2017) Chronic social defeat stress leads to changes of behaviour and memory-associated proteins of young mice. Behav Brain Res 316: 136\u2013144","journal-title":"Behav Brain Res"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1021\/acsptsci.0c00176","article-title":"Investigation of the Structure-Activity Relationships of Psilocybin Analogues","volume":"4","author":"Klein AK","year":"2021","unstructured":"Klein AK, Chatha M, Laskowski LJ, Anderson EI, Brandt SD, Chapman SJ, McCorvy JD, Halberstadt AL (2021) Investigation of the Structure-Activity Relationships of Psilocybin Analogues. ACS Pharmacol Transl Sci 4: 533\u2013542","journal-title":"ACS Pharmacol Transl Sci"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s00210-004-0951-4","article-title":"Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors","volume":"370","author":"Knight AR","year":"2004","unstructured":"Knight AR, Misra A, Quirk K, Benwell K, Revell D, Kennett G, Bickerdike M (2004) Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol 370: 114\u2013123","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/7854_2017_478","article-title":"Hallucinogens and Serotonin 5-HT(2A) Receptor-Mediated Signaling Pathways","volume":"36","author":"L\u00f3pez-Gim\u00e9nez JF","year":"2018","unstructured":"L\u00f3pez-Gim\u00e9nez JF, Gonz\u00e1lez-Maeso J (2018) Hallucinogens and Serotonin 5-HT(2A) Receptor-Mediated Signaling Pathways. Curr Top Behav Neurosci 36: 45\u201373","journal-title":"Curr Top Behav Neurosci"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1021\/jm060656o","article-title":"1-Aminomethylbenzocycloalkanes: conformationally restricted hallucinogenic phenethylamine analogues as functionally selective 5-HT2A receptor agonists","volume":"49","author":"McLean TH","year":"2006","unstructured":"McLean TH, Parrish JC, Braden MR, Marona-Lewicka D, Gallardo-Godoy A, Nichols DE (2006) 1-Aminomethylbenzocycloalkanes: conformationally restricted hallucinogenic phenethylamine analogues as functionally selective 5-HT2A receptor agonists. J Med Chem 49: 5794\u20135803","journal-title":"J Med Chem"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1016\/j.celrep.2019.02.104","article-title":"A Hallucinogenic Serotonin-2A Receptor Agonist Reduces Visual Response Gain and Alters Temporal Dynamics in Mouse V1","volume":"26","author":"Michaiel AM","year":"2019","unstructured":"Michaiel AM, Parker PRL, Niell CM (2019) A Hallucinogenic Serotonin-2A Receptor Agonist Reduces Visual Response Gain and Alters Temporal Dynamics in Mouse V1. Cell Rep 26: 3475\u20133483 e3474","journal-title":"Cell Rep"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0022-3956(94)00042-P","article-title":"Clinical and differential diagnostic aspects of treatment-resistant depression","volume":"29","author":"Nelsen MR","year":"1995","unstructured":"Nelsen MR, Dunner DL (1995) Clinical and differential diagnostic aspects of treatment-resistant depression. J Psychiatr Res 29: 43\u201350","journal-title":"J Psychiatr Res"},{"key":"ref33","first-page":"559","article-title":"Structure-activity relationships of serotonin 5-HT2Aagonists","volume":"1","author":"Nichols DE","year":"2012","unstructured":"Nichols DE (2012) Structure-activity relationships of serotonin 5-HT2Aagonists. Wiley Interdisciplinary Reviews: Membrane Transport and Signaling 1: 559\u2013579","journal-title":"Wiley Interdisciplinary Reviews: Membrane Transport and Signaling"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/pr.115.011478","volume":"68","author":"Nichols DE","year":"2016","unstructured":"Nichols DE (2016) Psychedelics. Pharmacol Rev 68: 264\u2013355","journal-title":"Psychedelics. Pharmacol Rev"},{"key":"ref35","first-page":"1","article-title":"Chemistry and Structure-Activity Relationships of Psychedelics","volume":"36","author":"Nichols DE","year":"2018","unstructured":"Nichols DE (2018) Chemistry and Structure-Activity Relationships of Psychedelics. Curr Top Behav Neurosci 36: 1\u201343","journal-title":"Curr Top Behav Neurosci"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.cell.2020.03.020","article-title":"Psychedelic Psychiatry's Brave New World","volume":"181","author":"Nutt D","year":"2020","unstructured":"Nutt D, Erritzoe D, Carhart-Harris R (2020) Psychedelic Psychiatry's Brave New World. Cell 181: 24\u201328","journal-title":"Cell"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S0140-6736(10)61462-6","article-title":"Drug harms in the UK: a multicriteria decision analysis","volume":"376","author":"Nutt DJ","year":"2010","unstructured":"Nutt DJ, King LA, Phillips LD, Independent Scientific Committee on D (2010) Drug harms in the UK: a multicriteria decision analysis. Lancet 376: 1558\u20131565","journal-title":"Lancet"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"113093","DOI":"10.1016\/j.bbr.2020.113093","article-title":"Investigating the role of 5-HT2A and 5-HT2C receptor activation in the effects of psilocybin, DOI, and citalopram on marble burying in mice","volume":"401","author":"Odland AU","year":"2021","unstructured":"Odland AU, Kristensen JL, Andreasen JT (2021) Investigating the role of 5-HT2A and 5-HT2C receptor activation in the effects of psilocybin, DOI, and citalopram on marble burying in mice. Behav Brain Res 401: 113093","journal-title":"Behav Brain Res"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1038\/s41386-022-01314-4","article-title":"Nicotinic receptors promote susceptibility to social stress in female mice linked with neuroadaptations within VTA dopamine neurons","volume":"47","author":"Ortiz V","year":"2022","unstructured":"Ortiz V, Costa Campos R, Fofo H, Fernandez SP, Barik J (2022) Nicotinic receptors promote susceptibility to social stress in female mice linked with neuroadaptations within VTA dopamine neurons. Neuropsychopharmacology 47: 1587\u20131596","journal-title":"Neuropsychopharmacology"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/jnc.15570","article-title":"In vitro assays for the functional characterization of (psychedelic) substances at the serotonin receptor 5-HT(2A) R","volume":"162","author":"Pottie E","year":"2022","unstructured":"Pottie E, Stove CP (2022) In vitro assays for the functional characterization of (psychedelic) substances at the serotonin receptor 5-HT(2A) R. J Neurochem 162: 39\u201359","journal-title":"J Neurochem"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.bbr.2005.07.013","article-title":"Implication of 5-HT2A subtype receptors in DOI activity in the four-plates test-retest paradigm in mice","volume":"166","author":"Ripoll N","year":"2006","unstructured":"Ripoll N, Hascoet M, Bourin M (2006) Implication of 5-HT2A subtype receptors in DOI activity in the four-plates test-retest paradigm in mice. Behav Brain Res 166: 131\u2013139","journal-title":"Behav Brain Res"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3389\/fnbeh.2020.00129","article-title":"Social Isolation Stress in Adolescence, but not Adulthood, Produces Hypersocial Behavior in Adult Male and Female C57BL\/6J Mice","volume":"14","author":"Rivera-Irizarry JK","year":"2020","unstructured":"Rivera-Irizarry JK, Skelly MJ, Pleil KE (2020) Social Isolation Stress in Adolescence, but not Adulthood, Produces Hypersocial Behavior in Adult Male and Female C57BL\/6J Mice. Front Behav Neurosci 14: 129","journal-title":"Front Behav Neurosci"},{"key":"ref43","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph15040771","article-title":"Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder","volume":"15","author":"Rong C","year":"2018","unstructured":"Rong C, Park C, Rosenblat JD, Subramaniapillai M, Zuckerman H, Fus D, Lee YL, Pan Z, Brietzke E, Mansur RB, Cha DS, Lui LMW, McIntyre RS (2018) Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder. Int J Environ Res Public Health 15","journal-title":"Int J Environ Res Public Health"},{"key":"ref44","first-page":"e17352","article-title":"Efficacy and Safety of Intranasal Esketamine in Treatment-Resistant Depression in Adults: A Systematic Review","volume":"13","author":"Sapkota A","year":"2021","unstructured":"Sapkota A, Khurshid H, Qureshi IA, Jahan N, Went TR, Sultan W, Alfonso M (2021) Efficacy and Safety of Intranasal Esketamine in Treatment-Resistant Depression in Adults: A Systematic Review. Cureus 13: e17352","journal-title":"Cureus"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"6756","DOI":"10.1038\/s41380-021-01145-7","article-title":"A novel murine model to study the impact of maternal depression and antidepressant treatment on biobehavioral functions in the offspring","volume":"26","author":"Scarborough J","year":"2021","unstructured":"Scarborough J, Mueller FS, Weber-Stadlbauer U, Mattei D, Opitz L, Cattaneo A, Richetto J (2021) A novel murine model to study the impact of maternal depression and antidepressant treatment on biobehavioral functions in the offspring. Mol Psychiatry 26: 6756\u20136772","journal-title":"Mol Psychiatry"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1021\/np030059u","article-title":"Concise large-scale synthesis of psilocin and psilocybin, principal hallucinogenic constituents of \"magic mushroom\"","volume":"66","author":"Shirota O","year":"2003","unstructured":"Shirota O, Hakamata W, Goda Y (2003) Concise large-scale synthesis of psilocin and psilocybin, principal hallucinogenic constituents of \"magic mushroom\". J Nat Prod 66: 885\u2013887","journal-title":"J Nat Prod"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S2215-0366(19)30533-4","article-title":"Approval of esketamine for treatment-resistant depression","volume":"7","author":"Singh JB","year":"2020","unstructured":"Singh JB, Daly EJ, Mathews M, Fedgchin M, Popova V, Hough D, Drevets WC (2020) Approval of esketamine for treatment-resistant depression. Lancet Psychiatry 7: 232\u2013235","journal-title":"Lancet Psychiatry"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"113971","DOI":"10.1016\/j.physbeh.2022.113971","article-title":"Role of sirtuin1 in impairments of emotion-related behaviors in mice with chronic mild unpredictable stress during adolescence","volume":"257","author":"Takaba R","year":"2022","unstructured":"Takaba R, Ibi D, Watanabe K, Hayakawa K, Nakasai G, Hiramatsu M (2022) Role of sirtuin1 in impairments of emotion-related behaviors in mice with chronic mild unpredictable stress during adolescence. Physiol Behav 257: 113971","journal-title":"Physiol Behav"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S2215-0366(19)30394-3","article-title":"Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval","volume":"6","author":"Turner EH","year":"2019","unstructured":"Turner EH (2019) Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval. Lancet Psychiatry 6: 977\u2013979","journal-title":"Lancet Psychiatry"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1176\/appi.ajp.2017.17040472","article-title":"The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis","volume":"175","author":"Wilkinson ST","year":"2018","unstructured":"Wilkinson ST, Ballard ED, Bloch MH, Mathew SJ, Murrough JW, Feder A, Sos P, Wang G, Zarate CA, Jr., Sanacora G (2018) The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. Am J Psychiatry 175: 150\u2013158","journal-title":"Am J Psychiatry"},{"key":"ref51","first-page":"699","article-title":"Direct injection of 5-HT2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats","volume":"282","author":"Willins DL","year":"1997","unstructured":"Willins DL, Meltzer HY (1997) Direct injection of 5-HT2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats. J Pharmacol Exp Ther 282: 699\u2013706","journal-title":"J Pharmacol Exp Ther"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1176\/appi.ajp.2008.08071027","article-title":"Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D report","volume":"166","author":"Wisniewski SR","year":"2009","unstructured":"Wisniewski SR, Rush AJ, Nierenberg AA, Gaynes BN, Warden D, Luther JF, McGrath PJ, Lavori PW, Thase ME, Fava M, Trivedi MH (2009) Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D report. Am J Psychiatry 166: 599\u2013607","journal-title":"Am J Psychiatry"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s12264-022-00933-7","article-title":"Non-hallucinogenic Psychedelic Analog Design: A Promising Direction for Depression Treatment","volume":"39","author":"Yin YN","year":"2023","unstructured":"Yin YN, Gao TM (2023) Non-hallucinogenic Psychedelic Analog Design: A Promising Direction for Depression Treatment. Neurosci Bull 39: 170\u2013172","journal-title":"Neurosci Bull"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1080\/14737175.2019.1554434","article-title":"An update on ketamine and its two enantiomers as rapid-acting antidepressants","volume":"19","author":"Zhang K","year":"2019","unstructured":"Zhang K, Hashimoto K (2019) An update on ketamine and its two enantiomers as rapid-acting antidepressants. Expert Rev Neurother 19: 83\u201392","journal-title":"Expert Rev Neurother"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-3138705\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-3138705\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T15:42:56Z","timestamp":1698680576000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-3138705\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,7]]},"references-count":54,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-3138705\/v1","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1007\/s00210-023-02778-x","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2023,7,7]]},"subtype":"preprint"}}